Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: Directors Deals Ltd.
$12.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zeltia SA Announces Negative Results From Phase II Trial Of Alzheimer Treatment-Reuters


Thursday, 11 Oct 2012 02:23am EDT 

Reuters reported that Zeltia SA’s Phase II trial of a drug for the treatment of Alzheimer did not achieve the intended objectives. The study evaluated the efficacy of Noscira’s drug tideglusib, versus placebo plus standard treatment in patients with mild-stage of Alzheimer. 

Company Quote

2.465
0.015 +0.61%
16 Apr 2014